Mednax, Inc (MD) Sets New 1-Year Low at $40.85
Mednax, Inc (NYSE:MD) shares hit a new 52-week low on Tuesday . The company traded as low as $40.85 and last traded at $41.01, with a volume of 1,557,527 shares trading hands. The stock had previously closed at $43.10.
A number of research analysts recently weighed in on the stock. Stephens upgraded shares of Mednax from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $55.00 to $68.00 in a report on Thursday, June 22nd. Stifel Nicolaus dropped their price objective on shares of Mednax from $65.00 to $58.00 and set a “hold” rating for the company in a report on Thursday, May 25th. Mizuho dropped their price objective on shares of Mednax from $64.00 to $58.00 and set a “neutral” rating for the company in a report on Tuesday, May 30th. BidaskClub upgraded shares of Mednax from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 13th. Finally, Jefferies Group LLC set a $46.00 price objective on shares of Mednax and gave the company a “hold” rating in a report on Sunday, July 30th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $58.89.
The company has a 50-day moving average of $43.21 and a 200-day moving average of $56.37. The stock has a market capitalization of $3.88 billion, a P/E ratio of 13.42 and a beta of 0.40.
Mednax (NYSE:MD) last issued its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company had revenue of $843.00 million during the quarter, compared to the consensus estimate of $849.49 million. During the same quarter last year, the company earned $1.03 earnings per share. Mednax’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, equities analysts forecast that Mednax, Inc will post $3.31 earnings per share for the current fiscal year.
In other Mednax news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of MD. QS Investors LLC grew its position in shares of Mednax by 0.3% during the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after buying an additional 12 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Mednax by 0.5% during the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock worth $632,000 after buying an additional 47 shares in the last quarter. Pacer Advisors Inc. grew its position in shares of Mednax by 3.2% during the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock worth $125,000 after buying an additional 55 shares in the last quarter. Nomura Asset Management Co. Ltd. grew its position in shares of Mednax by 1.3% during the first quarter. Nomura Asset Management Co. Ltd. now owns 11,300 shares of the company’s stock worth $784,000 after buying an additional 140 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Mednax by 1.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,656 shares of the company’s stock worth $1,017,000 after buying an additional 164 shares in the last quarter.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.